文献速递免疫规划传染病防控与疫情报告

稳定乳剂(SE)单独即可作为重组杆状病毒表达H5流感疫苗的有效佐剂:一项健康成人2期试验

Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial.
PubMed 文献 · Vaccine · 2017-01-11

健康成人18-49岁随机分组,分别接种无佐剂7.5微克或含2%稳定乳剂(SE)的3.8、7.5、15微克重组血凝素(rHA)疫苗两剂,间隔21天。无佐剂组血清转化率仅9%(95%CI 4%,17%),三个含SE佐剂组分别为70%(59%,80%)、76%(65%,85%)、83%(73%,91%)。结论认为SE单独即为有效佐剂,三个含佐剂剂量组均达到当前大流行疫苗血清转化率标准。

要点

  • 无佐剂7.5微克组两剂后血清转化率仅9%(95%CI 4%,17%)。
  • 含2%SE的3.8、7.5、15微克组血清转化率分别为70%、76%、83%。
  • 15微克加2%SE组同时满足血清转化率和HI抗体滴度≥40受试者比例两项标准。

核心结论

  • 稳定乳剂单独即为健康成人重组H5疫苗的有效佐剂。
  • 三个含2%SE的佐剂剂量组均达到当前大流行疫苗血清转化率标准。
  • 15微克加2%SE组同时满足血清转化率和HI抗体滴度≥40受试者比例两项标准。
  • 上述2期数据支持含SE佐剂的Panblok H5疫苗进一步临床开发。

研究设计与样本

  • 健康受试者18-49岁按1:1:1:1随机分组。
  • 各组分别接种两剂rHA:无佐剂7.5微克,或含2%SE的3.8微克、7.5微克、15微克,两剂间隔21天。
  • 于第0、21、42、201天采集血清,以血细胞凝集抑制试验评估。
  • 共入组341名受试者,其中321名完成两剂接种。

主要发现

  • 所有组接种耐受良好。
  • 两剂后无佐剂7.5微克组血清转化率为9%(95%CI 4%,17%)。
  • 含2%SE的3.8微克组血清转化率为70%(95%CI 59%,80%)。
  • 含2%SE的7.5微克组血清转化率为76%(95%CI 65%,85%)。
  • 含2%SE的15微克组血清转化率为83%(95%CI 73%,91%)。

关键数值与推荐

  • 三个含2%SE的佐剂剂量组均达到当前大流行疫苗血清转化率标准。
  • 15微克加2%SE组同时达到血清转化率和HI抗体滴度≥40受试者比例两项标准。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Influenza A viruses of the H5 subtype have been identified as important targets for development of vaccines. Achievement of potentially protective antibody responses against pandemic strains has usually required the use of adjuvants. OBJECTIVES: We evaluated a candidate A/Indonesia/05/2005 (H5) vaccine generated by baculovirus expression of recombinant hemagglutinin (HA) protein with or without stable emulsion (SE) as an adjuvant. METHODS: Healthy subjects 18-49years old were randomized (1:1:1:1) to receive two doses of rHA at 7.5ug per dose (no adjuvant), or 3.8ug, 7.5ug, or 15ug per dose formulated with 2% SE separated by 21days, and serum from day 0, 21, 42, and 201 assessed by hemagglutination-inhibition. RESULTS: 341 subjects were enrolled in the study and 321 received two doses of vaccine. Vaccination was well tolerated in all groups. After two doses, seroconversion was noted in only 9% (95% confidence interval 4%, 17%) of recipients of unadjuvanted vaccine at 7.5ug, but in 70% (59%, 80%), 76% (65%, 85%), and 83% (73%, 91%) of those receiving adjuvanted vaccine at 3.8ug, 7.5ug, or 15ug respectively. CONCLUSIONS: Stable emulsion alone is an effective adjuvant for rH5 vaccine in healthy adults. All three adjuvanted dose groups met the current criterion for seroconversion rate for pandemic vaccines. This dose-ranging study also identified a group (15ug per dose formulated with 2% SE) that met the criteria for both seroconversion and percentage of subjects achieving an HI antibody titer⩾40. These Phase 2 data support the further clinical development of SE adjuvanted Panblok H5. CLINICAL TRIAL REGISTRATION: NCT01612000. The protocol was approved by the relevant Institutional Review Board for each study site, and the study was conducted in accordance with the Declaration of Helsinki, International Conference of Harmonisation - Good Clinical Practice, and all applicable laws and regulations. All participants provided written informed consent before study procedures.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Treanor JJ, Chu L, Essink B, et al. Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial. Vaccine. 2017. PMID: 28089141. doi:10.1016/j.vaccine.2016.12.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。